Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
Onconova Therapeutics, Inc. (ONTX) to Present at Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
11/28/2023 - 08:00 AM
NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference, being held December 3-5, 2023 at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.
Presentation Details
Date/Time: Monday, December 4, 2023, 10:30 AM ET followed by a Breakout Session Speaker: Steven Fruchtman, M.D., President & CEO 1X1 meetings: The Onconova Management Team will be available for 1X1 meetings during the conference. Those interested in requesting a meeting should contact their Noble Capital Markets representative.
A webcast of the presentation will be available the following day on the “Corporate Events and Presentations ” section of the Onconova website, and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website www.nobleconference.com , and on Channelchek www.channelchek.com . The webcast will be archived on the Onconova website, the NobleCon website, and on Channelchek.com for 90 days following the event.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company’s product candidates, narazaciclib and rigosertib, are proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Narazaciclib, Onconova’s novel, multi-kinase inhibitor (formerly ON 123300), is being evaluated in a Phase 1/2 combination trial with the estrogen blocker letrozole, in advanced endometrial cancer (NCT05705505 ). Based on preclinical and clinical studies of CDK 4/6 inhibitors, Onconova believes narazaciclib has broad potential and is also evaluating opportunities for combination studies with narazaciclib and letrozole in additional indications, including breast cancer, ovarian cancer and mantle cell lymphoma.
Rigosertib is being studied in an investigator-sponsored trial strategy to evaluate the product candidate in multiple indications, including a dose-escalation and expansion Phase 1/2a study of oral rigosertib in combination with nivolumab in patients with KRAS+ non-small cell lung cancer (NCT04263090 ), a Phase 2 program evaluating oral or IV rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC) (NCT03786237 , NCT04177498 ), and a Phase 2 trial evaluating rigosertib in combination with pembrolizumab in patients with metastatic melanoma (NCT05764395 ).
For more information, please visit www.onconova.com .
Company Contact: ir@onconova.us https://www.onconova.com/contact/
Investor Contact: bmackle@lifesciadvisors.com
When is Onconova Therapeutics, Inc. (ONTX) presenting at NobleCon19?
Onconova Therapeutics, Inc. (ONTX) will present at NobleCon19 on Monday, December 4, 2023, at 10:30 AM ET followed by a Breakout Session.
Who will be the speaker at the presentation?
Steven Fruchtman, M.D., President & CEO of Onconova Therapeutics, Inc. (ONTX) will be the speaker at the presentation.
Where will the conference be held?
The conference will be held at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.
Will the presentation be available for webcast?
Yes, a webcast of the presentation will be available the following day on the 'Corporate Events and Presentations' section of the Onconova website, and on Noble Capital Markets’ Conference website and Channelchek.
How long will the webcast be available for viewing?
The webcast will be archived on the Onconova website, the NobleCon website, and on Channelchek.com for 90 days following the event.
Onconova Therapeutics Inc
ONTX Rankings
#2950 Ranked by Stock Gains
ONTX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Newtown
About ONTX
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
